Valbenazine is primarily used in the treatment of tardive dyskinesia, a neurological disorder characterized by involuntary, repetitive body movements. It works by regulating dopamine levels in the brain, specifically through the inhibition of vesicular monoamine transporter 2 (VMAT2), which helps reduce the severity of abnormal movements. This medication is often prescribed to patients who have developed tardive dyskinesia as a side effect of long-term use of antipsychotic drugs. It is administered orally and is typically part of a broader treatment plan that may include other therapies or medications. Valbenazine has shown efficacy in improving symptoms and enhancing the quality of life for affected individuals. Regular monitoring by a healthcare provider is essential to manage potential side effects and ensure optimal dosing.